Literature DB >> 20434895

Empowering malaria vaccination by drug administration.

Robert W Sauerwein1, Else M Bijker, Thomas L Richie.   

Abstract

Although significant progress has been made in clinical development, a protective malaria vaccine remains elusive. Here we review some of the immune subversive mechanisms used by the Plasmodium malaria parasite and propose a potentially effective strategy to achieve complete protection that may serve as a blue print for clinical usage. The premise is to modulate the immune response with drugs that neutralize suppressive functions and potentiate protective responses. Chloroquine may be a first attractive candidate facilitating protective cellular immune responses by improving cross-presentation and reducing suppressive regulatory T cell responses. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434895     DOI: 10.1016/j.coi.2010.04.001

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  8 in total

Review 1.  Cross-presentation by dendritic cells.

Authors:  Olivier P Joffre; Elodie Segura; Ariel Savina; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

Review 2.  Imaging Plasmodium immunobiology in the liver, brain, and lung.

Authors:  Ute Frevert; Adéla Nacer; Mynthia Cabrera; Alexandru Movila; Maike Leberl
Journal:  Parasitol Int       Date:  2013-09-27       Impact factor: 2.230

3.  Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin.

Authors:  I G Azcárate; P Marín-García; N Camacho; S Pérez-Benavente; A Puyet; A Diez; L Ribas de Pouplana; J M Bautista
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

4.  Parasitostatic effect of maslinic acid. II. Survival increase and immune protection in lethal Plasmodium yoelii-infected mice.

Authors:  Carlos Moneriz; Patricia Marín-García; José M Bautista; Amalia Diez; Antonio Puyet
Journal:  Malar J       Date:  2011-04-25       Impact factor: 2.979

5.  Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans.

Authors:  Anne C Teirlinck; Matthew B B McCall; Meta Roestenberg; Anja Scholzen; Rob Woestenenk; Quirijn de Mast; Andre J A M van der Ven; Cornelus C Hermsen; Adrian J F Luty; Robert W Sauerwein
Journal:  PLoS Pathog       Date:  2011-12-01       Impact factor: 6.823

6.  Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii.

Authors:  Rubul Mout; Zhi-Dong Xu; Angela K H Wolf; Vincent Jo Davisson; Gotam K Jarori
Journal:  Malar J       Date:  2012-02-23       Impact factor: 2.979

7.  Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial.

Authors:  Else M Bijker; Remko Schats; Joshua M Obiero; Marije C Behet; Geert-Jan van Gemert; Marga van de Vegte-Bolmer; Wouter Graumans; Lisette van Lieshout; Guido J H Bastiaens; Karina Teelen; Cornelus C Hermsen; Anja Scholzen; Leo G Visser; Robert W Sauerwein
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

8.  Experimental Immunization Based on Plasmodium Antigens Isolated by Antibody Affinity.

Authors:  Ali N Kamali; Patricia Marín-García; Isabel G Azcárate; Antonio Puyet; Amalia Diez; José M Bautista
Journal:  J Immunol Res       Date:  2015-10-11       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.